September 20, 2018 06:43 AM EDTUpdated 06:54 AM

With new $10.6B fund, Hillhouse Capital sets the stage for splashy Asia-focused biotech deals

Amber Tong

Having thrown its weight behind some of the biggest biotech financing rounds of the year, China’s private equity powerhouse Hillhouse Capital has reloaded …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With new $10.6B fund, Hillhouse Capital sets the stage for splashy Asia-focused biotech deals

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Updated: Judge halts NIH cuts nationwide after groups, 22 states sue

Vertex operations chief Stuart Arbuckle to retire

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

With new $10.6B fund, Hill­house Cap­i­tal sets the stage for splashy Asia-fo­cused biotech deals

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With new $10.6B fund, Hillhouse Capital sets the stage for splashy Asia-focused biotech deals